Aquestive Therapeutics, Inc. (AQST) Stock Forecast
AQST analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.78 / 5 from 9 analysts
- Price target
- $9.33 average of analyst targets
- Upside to target
- +146.9% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.10
- 52-week range
- $2.95 – $7.49
AQST analyst ratings
9 analystsNumber of analysts at each rating.
AQST price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AQST earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.15 | −$0.12 | −$0.11 | −17.8% | 2 |
| Current fiscal year (2026) | −$0.45 | −$0.45 | −$0.45 | −$0.59 | +23.6% | 2 |
| Next fiscal year (2027) | −$0.57 | −$0.70 | −$0.44 | −$0.45 | −26.7% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AQST revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $11.0M | $9.9M | $11.6M | −14.0% | 9 |
| Current fiscal year (2026) | $51.0M | $49.2M | $59.3M | +14.6% | 9 |
| Next fiscal year (2027) | $67.8M | $52.2M | $112.0M | +32.8% | 9 |
AQST EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AQST revenue: reported and forecast
AQST EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.12 | −$0.12 | −$0.12 | −$0.14 | +22.7% | 0 up · 2 down |
| Current fiscal year (2026) | −$0.46 | −$0.42 | −$0.42 | −$0.42 | −$0.45 | −2.2% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.58 | −$0.45 | −$0.45 | −$0.45 | −$0.57 | −1.7% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AQST earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AQST beat in 5 of 12.
What analysts expect from AQST
9 analysts cover Aquestive Therapeutics; their consensus rating is strong buy (4.78 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.33, 146.9% above the latest close of $3.78. Analysts expect earnings of −$0.45 per share for 2026, +23.6% from a year earlier. For 2027 the average estimate is −$0.57 per share on revenue of $67.8 million. Aquestive Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: AQST income statement, AQST key metrics, AQST chart. See the AQST stock overview for the latest quote and news.
AQST forecast FAQ
What is Aquestive Therapeutics's price target?
The average analyst price target for Aquestive Therapeutics is $9.33, 146.9% above the latest close of $3.78.
Is Aquestive Therapeutics a buy, hold or sell?
Of 9 analysts covering Aquestive Therapeutics, 7 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Aquestive Therapeutics's EPS forecast?
Analysts forecast −$0.45 per share for 2026 (range −$0.45 to −$0.45); for 2027 the estimate is −$0.57.
What is Aquestive Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $51.0 million, growth of 14.6%; for 2027 it is $67.8 million.
When does Aquestive Therapeutics report earnings?
Aquestive Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.10.
Does Aquestive Therapeutics usually beat earnings estimates?
Aquestive Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.